AbbVie has announced the U.S. Food and Drug Administration (FDA) approval for RINVOQ (upadacitinib) to treat refractory, moderate to severe atopic dermatitis in children 12 years and older and adults. Atopic dermatitis, more commonly known as eczema, is a chronic skin condition characterized by red, inflammatory rashes. RINVOQ (upadacitinib) is a selective Janus kinase (JAK) inhibitor to treat patients whose condition could not treated initially with systemic therapy. Currently, RINVOQ (upadacitinib) is also approved to treat patients with rheumatoid arthritis and psoriatic arthritis. Atopic dermatitis is a long-term skin condition that is typically managed with a number of antihistamines, corticosteroids, antibiotics, and topical immunomodulators. AbbVie is a US-based pharmaceutical develops innovative medicines to treat health issues in key areas including immunology, oncology, virology, and gastroenterology.
Read more here.